RxDoctor Payments Data

Casey Owens, MD

Gastroenterology · American Fork, UTNPI 1437348943

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.3% of the total across 329 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 29 manufacturers reported payments, led by AbbVie at 53.2% of the total.

$5,837in general payments, 2019–2025

Across 329 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Johnson & Johnson$494
  • Takeda Pharmaceuticals U.S.A., Inc.$458
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$220
  • Pfizer$210
  • Aimmune Therapeutics, Inc.$112
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$5,73998%
  • Education$982%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,837 in reported general payments places this provider in the 75th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah

Medicare billing

Part B allowed, 2024
$67,514
Medicare patients
318
Services billed
760

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab24$182,259
Omeprazole387$6,233
Colestipol Hcl127$6,119
Mesalamine19$6,037
Budesonide DrBudesonide18$2,425
Sucralfate47$1,921
Ursodiol17$1,824
Balsalazide Disodium11$1,738
Azithromycin44$1,716
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl75$1,480
Pantoprazole Sodium65$776
MethotrexateMethotrexate Sodium36$738
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl39$697
Lansoprazole16$317
Esomeprazole Magnesium15$307

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SandozLansoprazole$14$31716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 122 gastroenterology providers in Utah.

Other gastroenterology in American Fork

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →